The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. Otarmeni is indicated for the ...
The FDA has approved Otarmeni, the first-ever gene therapy for genetic hearing loss caused by the OTOF gene, for both ...
US FDA approves Regeneron’s gene therapy, Otarmeni for genetic hearing loss: Tarrytown, New York Regeneron Pharmaceuticals, Inc., a leadi ...
MedPage Today on MSN
First Gene Therapy Approved for Hearing Loss
Maker says Otarmeni will be offered for free in the U.S.
Health and Me on MSN
US FDA approves 1st-ever gene therapy for treatment of genetic hearing loss
Developed by American Biotechnology company Regeneron, Otarmeni has been approved for the treatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss. The ...
Morning Overview on MSN
Gene therapy restored hearing in 90% with OTOF deafness, study says
A single injection into the inner ear restored functional hearing in 90% of people born deaf because of mutations in the OTOF ...
Creative Biolabs is helping researchers overcome challenges of gene therapy research by providing analytical testing and quality control services. SHIRLEY, NY, UNITED ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results